Gain Therapeutics Inc (NAS:GANX)
$ 2.55 0.04 (1.59%) Market Cap: 46.03 Mil Enterprise Value: 33.54 Mil PE Ratio: 0 PB Ratio: 5.24 GF Score: 59/100

Gain Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 28, 2022 / 06:00PM GMT
Release Date Price: $3.51 (+3.85%)
Mayank Mamtani
B. Riley Securities, Inc. - Analyst

Good afternoon, and good morning to folks on the West Coast. And thanks for joining us for our next company fireside chat with Gain Therapeutics' Chief Operating Officer, Matthias Alder.

Thank you for taking out time of your busy schedule. I know you have a lot going on at Gain. Maybe at the highest level, talk a little bit about the company overview, pipeline, how should we think about some of the milestones in the next several years.

Matthias Alder
Gain Therapeutics, Inc. - COO

Absolutely. Thank you, Mayank, and thanks for the opportunity to talk here this afternoon, or morning on the West Coast.

So just to give you -- for people who are not familiar with Gain, give you a bit of a background about the company first. So we are a preclinical-stage company, biotech company. We were established in 2017.

And the core of the company is based around a physics-based computational drug-discovery platform that was developed by our Chief Technology Officer, Xavier Barril, at the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot